Boston Scientific wins Canadian court dismissal of J&J suit

Follica snags $11M in second round to prevent hair loss [August 12, 2008]

Alkermes seeks FDA nod for bipolar disorder drug [July 24, 2008]

Big pharmas target addiction as depression drugs come off patent [July 11, 2008]

Aspect Medical to boost U.S. sales force head count [May 30, 2008]

A Canadian court has dismissed a lawsuit from Johnson & Johnson against Boston Scientific Corp. for infringing on two of Johnson & Johnson's patents related to stents, according to Boston Scientific.

Natick-based Boston Scientific (NYSE: BSX) and medical products powerhouse Johnson & Johnson are arch competitors in the multibillion-dollar market for stents, which are metal tubes used to prop open arteries after surgeries to remove blockages.

Johnson & Johnson, based in New Jersey, claimed in the now-dismissed lawsuit that Boston Scientific's NIR stent infringed on the two patents. Yet Boston Scientific said it faces a separate lawsuit from Johnson & Johnson in which its competitor claims that its Taxus and Express stents infringe on the same two patents.

Boston Scientific, a global developer, manufacturer and distributor of medical devices, reported a 2007 net loss of $495 million on revenue of $8.4 billion. The firm employed 27,500 workers worldwide as of December 2007.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.